product summary
company name :
Cell Signaling Technology
product type :
ELISA/assay
product name :
PathScan® Phospho-Akt2 (Ser474) Sandwich ELISA Kit
catalog :
7048S
quantity :
1 Kit
price :
481 USD
more info or order :
product information
SKU :
7048S
Product-Name :
PathScan® Phospho-Akt2 (Ser474) Sandwich ELISA Kit
Size :
1 Kit
Price-(USD) :
481 USD
Species-x-Reactivity :
H, M
Applications :
Enzyme Linked Immunosorbent Assay
Product-Category :
PI3K / Akt Signaling
Shipping-Temp :
COLD
Storage-Temp :
4°C
Product-Type :
ELISA Kit
MW :
60
Target :
Akt2 (Ser474) phosphate
Primary-Protein :
Akt2
Alt-Names :
AKT2,Murine thymoma viral (v-akt) homolog-2,PKB beta,PKBB,PKBBETA,PRKBB,Protein kinase Akt-2,Protein kinase B beta,RAC-BETA,RAC-PK-beta,RAC-beta serine/threonine-protein kinase,rac protein kinase beta,v-akt murine thymoma viral oncogene homolog 2
more info or order :
company information
Cell Signaling Technology
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.
review
product type
related products
browse more products
- PathScan® Phospho-p70 S6 Kinase (Thr389) Sandwich ELISA Kit
- PathScan® Total Insulin Receptor β Sandwich ELISA Kit
- PathScan® Phospho-Insulin Receptor β (panTyr) Sandwich ELISA Kit
- PathScan® Total ALK Chemiluminescent Sandwich ELISA Kit
- PathScan® Total ROS1 Sandwich ELISA Kit
- PathScan® Phospho-ROS1 (panTyr) Sandwich ELISA Kit
- PathScan® Phospho-TrkB (panTyr) Sandwich ELISA Kit
- PathScan® Phospho-TrkB (Tyr516) Sandwich ELISA Kit
questions and comments